Mar 16, 2022
Proceeds to support 2seventy bio’s pipeline of novel cell therapy programs Financing, combined with reduced net cash spend and ABECMA commercial progress, supports extension of cash runway into 2025 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2022-- 2seventy bio, Inc .
Feb 14, 2022
Steven Bernstein , M.D. appointed to chief medical officer Susan Abu-Absi , Ph.D. promoted to chief technology & manufacturing officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2022-- 2seventy bio, Inc . (NASDAQ: TSVT) announced that Steven Bernstein , M.D.
Feb 14, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference; Fireside chat, Wednesday, February 16, 2022 , at 2:20pm ET Cowen Virtual
Jan 11, 2022
ABECMA generated approximately $150M   U.S. revenue in 2021, equally shared by 2seventy bio and Bristol Myers Squibb; anticipate continued ABECMA growth in 2022 with $250-300M   U.S. revenue bbT369 IND cleared - program tests three layers of innovation in B-NHL; achieved goal of two new INDs